(Total Views: 784)
Posted On: 12/22/2020 9:19:43 PM
Post# of 149051
But Ohm20, why, in heaven's name, would the FDA be so circuitous?
Surely, they know exactly what they're doing, right?
Nov 19, 2020
Lenacapavir (previously GS-6207) is the first in a new class of class HIV-1 capsid inhibitor that Gilead is hoping will eventually free patients from the need to take daily oral tablets, although initially it is being developed for patients who are failing their current treatment regimen.
Data sets up 2021 filings for Gilead’s twice-a-year HIV drug lenacapavir
November 19, 2020
Gilead Sciences has the data it was hoping for in a pivotal trial of lenacapavir, an HIV drug that only needs to be dosed by subcutaneous injection every six months, keeping it on course for regulatory filings next year.
The drug is also a key part of Gilead’s plans to defend its $16 billion HIV franchise from rivals which are also developing long-acting injectables, namely ViiV Healthcare with cabotegravir and Merck & Co’s islatravir (MK-8591).
https://pharmaphorum.com/news/data-sets-up-20...%20regimen.
Surely, they know exactly what they're doing, right?
Nov 19, 2020
Lenacapavir (previously GS-6207) is the first in a new class of class HIV-1 capsid inhibitor that Gilead is hoping will eventually free patients from the need to take daily oral tablets, although initially it is being developed for patients who are failing their current treatment regimen.
Data sets up 2021 filings for Gilead’s twice-a-year HIV drug lenacapavir
November 19, 2020
Gilead Sciences has the data it was hoping for in a pivotal trial of lenacapavir, an HIV drug that only needs to be dosed by subcutaneous injection every six months, keeping it on course for regulatory filings next year.
The drug is also a key part of Gilead’s plans to defend its $16 billion HIV franchise from rivals which are also developing long-acting injectables, namely ViiV Healthcare with cabotegravir and Merck & Co’s islatravir (MK-8591).
https://pharmaphorum.com/news/data-sets-up-20...%20regimen.
(3)
(0)Scroll down for more posts ▼
